Tag archive for ‘cerdulatinib phase 2 trial in PTCL’
Portola: Update and Reiteration of Buy Recommendation (PTLA, Buy, $39.31)
Investment Thesis in Brief This report is based on presentations by management at recent brokerage conferences. It is an update and not a comprehensive analysis of Portola. For more detailed analysis, you may want to refer to a series of reports on my website. I am reiterating my Buy recommendation on Portola. I have a […]